CJC-1295 (no DAC) vs CJC-1295 with DAC

CJC-1295 (no DAC)

A short-acting GHRH analogue — the GH pulse it produces is sharp, brief, and very close to what the pituitary does on its own. Stabilised against rapid breakdown, but without the albumin-binding modification that turns it into the long-acting DAC version.

Best for

Best when you want clean pulses that align with natural GH release (nightly dosing, off-cycle sensitivity intact for longer).

CJC-1295 with DAC

The long-acting version: the same GHRH analogue plus a Drug Affinity Complex that lets it bind albumin reversibly, stretching the half-life from minutes to days. Convenience peptide — one shot a week — at the cost of the pulsatile pattern.

Best for

Best when you want once-weekly convenience and accept faster receptor desensitisation as the trade.

CJC-1295 (no DAC)

The pulse-amplification pharmacology is well-characterised in short human studies — Teichman and colleagues (2006) is the canonical reference and the half-life and pulse-shape data is solid. What is missing is long-term outcome data in healthy adults. The chronic safety profile is reassuring by absence of major signals across two decades of grey-market use, but absence of signal is not the same as a chronic safety trial.

CJC-1295 with DAC

The half-life extension and the sustained IGF-1 elevation are pharmacologically well-characterised — Teichman and colleagues (2006) is again the original pharmacokinetic paper. Long-term body-composition or safety data in healthy adults is sparse. The receptor-desensitisation concern is mechanistic rather than from a head-to-head trial against no-DAC, but the basic-science case is strong enough that the cycling pattern (8 on, 4 off) is the conventional answer.